Overview |
bs-13059R-Cy5.5 |
EFEMP2/Fibulin 4 Polyclonal Antibody, Cy5.5 Conjugated |
WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
Specifications |
Cy5.5 |
Rabbit |
KLH conjugated synthetic peptide derived from human EFEMP2/Fibulin 4 |
331-443/443 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
30008 |
Secreted |
EFEMP2; EGF containing fibulin like extracellular matrix protein 2; EGF-containing fibulin-like extracellular matrix protein 2; FBLN 4; FBLN4; FBLN4_HUMAN; FIBL 4; FIBL-4; FIBL4; Fibulin4; Fibulin-4; MBP 1; MBP1; Mutant p53 binding protein 1; Protein UPH1; UPH 1; UPH1; UPH1 protein. |
Fibulin proteins contribute to normal development of elastic fiber systems in various types of organs that require elasticity, such as vasculature, lung and skin. Fibulin-4, also known as EFEMP2 (EGF-containing fibulin-like extracellular matrix protein 2), MBP1 or UPH1 is a 443 amino acid secreted protein that contains six EGF-like calcium-binding domains and belongs to the fibulin family. Expressed ubiquitously with highest expression in heart, Fibulin-4 is essential for connective tissue development and elastic fiber formation, and may also play an important role in vascular patterning and collagen biosynthesis. Defects in the gene encoding Fibulin-4 are associated with autosomal recessive cutis laxa type I (CL type I), a connective tissue disorder that is inherited in both an autosomal dominant and an autosomal recessive manner and is characterized by inelastic tissue in all affected areas of the body. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |